吉西他滨联合奥沙利铂治疗胰腺癌的疗效观察

Observation on the Therapeutic Effect of Gemcitabine Combined with Oxaliplatin in the Treatment of Pancreatic Cancer

目的探讨吉西他滨联合奥沙利铂治疗胰腺癌的临床治疗效果及安全性,为临床用药提供依据。方法选择2010年8月～2011年6月在我院肿瘤科治疗的58例胰腺癌患者,随机分为两组,每组29例,对照组患者单用吉西他滨治疗,观察组给予吉西他滨联合奥沙利铂治疗,比较两组患者治疗后的客观有效率、不良反应及生存期。结果对照组患者的客观有效率为79.3%(23/29),观察组患者的客观有效率为96.6%(28/29),显著高于对照组(P<0.05);对照组患者的临床受益率为58.6%(17/29),观察组患者的临床受益率为75.9%(22/29),亦较对照组显著升高(P<0.05);观察组患者不良反应的发生率显著低于对照组(P<0.05),患者的平均生存时间(6.8±1.3年)显著长于对照组(2.3±1.1年),组间差异具有统计学意义(P<0.05)。结论吉西他滨联合奥沙利铂治疗胰腺癌较单用吉西他滨可以显著提高治疗的客观有效率,延长患者的生存期,并降低药物的不良反应,值得临床推广使用。

Objective To study the clinical efficacy and safety of gemcitabine combined oxaliplatin in the treatment of pancreatic cancer and provide references for the further clinical application. Methods 58 cases of pancreatic cancer patients admitted in our hospital from August 2010 to June 2011were randonfly divided into two groups （29 cases in each group）. The control group was treated by gemcitabine, while the observation group was given gemcitabine combined oxaliplatin. The objective response rate, adverse reaction and survival period were compared between the two groups. Results The objective response rate of observation group was 96.6 %, （28/29）, which was significantly higher than that of the control group （79.3 %, P〈0.05）. The clinical benefit rate of observation group was 75.9% （22/29）, which was also significantly higher than that of the control group （58.6 %, P〈 0.05）. The incidence rate of adverse reactions of the observation group was significantly lower than that of the control group （P〈0.05）. The average survival time of observation group was 6.8 ± 1.3 years, which was obviously longer than that of the control group （2.3 ±1.1） （P 〈 0.05）. Conclusion Compared with treatment with Gemcitabine alone, Gemcitabine combined with oxaliplatin may effectively improve the objective response rate, prolong the survival period, and reduce the adverse reaction of patients with pancreatic cancer. It is worth of clinical application. Key words： Gemcitabine; Oxaliplatin into; Pancreatic cancer; Clinical effect; Safety